C11155: Method of developing targeted therapeutic agents for cancer using adenovirus
Value Proposition:
• Addresses a major patient need.
• Specific for the target.
• Enhances adenoviral gene therapy.
• Has therapeutic and diagnostic applications.
Technical Details:
JHU scientists have developed a successful strategy to optimize targeted viral infection using adenovirus. A phage-derived peptide, targeting the Prostate Specific Membrane Antigen (PSMA), was genetically incorporated into the adenoviral capsid protein, Fiber, and flanked by random peptide cassettes. The selected virus preferentially infected PSMA-expressing cells through the targeting peptide and also infected prostate cancer xenografts after intravenous injection. This approach represents a novel principle for developing targeted therapeutic agents for various cancers.
Looking for Partners:
Potential targeted agents for prostate cancer, or other cancers, not only in adenovirus but also in other experimental therapeutic platforms
Patent Status: Pending US Application US-2013-0315870
Publications/Associated Cases:
Wu P. et al (2010) Adenovirus Targeting to Prostate-specific Membrane Antigen through Virus-displayed Semi-random Peptide Library Screening. Cancer Res. 2010 Jul 29. [Epub ahead of print]
